medicare coverage for glp 1 drugs cuts cost of popular GLP-1 weight-loss eligible seniors Medicare expands access to GLP-1
Description
Accessed April 28, 2020
Metabolism Following a [14C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin
While during this time frame the percentage of new users with type 2 diabetes decreased, there was a twofold increase in the proportions of users without type 2 diabetes and a BMI of 30 kg/m 2 or greater, as well as in participants with a BMI of 27 to 30 kg/m 2 and an obesity-related comorbid condition
January 12, 2024
The biological pathways remain active, but receptor stimulation is lower
